While drugmakers are hard at work on the shots, they’re not yet ready to blunt the impact of a potential pandemic.
Stargate CEOs cite project’s promise of enabling cancer vaccines, though Musk joins critics in questioning partners’ ...
Traditional vaccines typically focus on the most accessible parts of viruses, which are often the rapidly mutating ...
The next phase of pre-exposure prophylaxis against SARS-CoV-2 currently rests on the shoulders of a single monoclonal ...
A new experimental vaccine developed by researchers at MIT and Caltech could offer protection against emerging variants of SARS-CoV-2, as well as related coronaviruses, known as sarbecoviruses, that ...
Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...
Engineering and medical researchers at Penn have developed a groundbreaking framework that can determine the best and most ...
At J.P. Morgan, most biopharma executives expressed a neutral stance on the incoming administration, but just days later, ...
Plus: Moderna’s bird flu vaccine, Obamacare enrollment breaks records, and AstraZeneca’s new breast cancer treatment is FDA ...
The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...
GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I've ...
The article " After a Reset Year, Is Moderna Stock Poised for a Comeback? " first appeared on MarketBeat.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback